BWAY Brainsway

BrainsWay’s Deep TMS Takes Center Stage at Clinical TMS Society Annual Poster Session

BrainsWay’s Deep TMS Takes Center Stage at Clinical TMS Society Annual Poster Session
EN
06/10/2020

Underlying

BWAYBrainsway

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Brainsway

 PRESS RELEASE
Free
BWAY BRAINSWAY

BrainsWay Reports Positive Results from Multicenter Randomized Study o...

BrainsWay Reports Positive Results from Multicenter Randomized Study of Accelerated Deep TMS for Major Depressive Disorder (MDD) Improvement in depression scores, response and remission were all found to be comparable with standard Deep TMS in non-inferiority trial BURLINGTON, Mass. and JERUSALEM, June 11, 2025 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced preliminary results from a multicenter, randomized controlled trial titled, “Accelerated Deep TMS for Depress...

June 11, 2025 1 EN
 PRESS RELEASE
Free
BWAY BRAINSWAY

BrainsWay Announces Gold Sponsorship at the 2025 Clinical TMS Society ...

BrainsWay Announces Gold Sponsorship at the 2025 Clinical TMS Society Annual Meeting in San Diego Deep TMS Takes Center Stage with Compelling Research BURLINGTON, Mass. and JERUSALEM, June 10, 2025 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, proudly announces its Gold Sponsorship of the Clinical TMS Society’s 2025 Annual Meeting, taking place June 12–14 in San Diego, CA. BrainsWay’s participation will spotlight its industry-leading Deep Transcranial Magnetic Stimulation (Deep T...

June 10, 2025 1 EN
 PRESS RELEASE
Free
BWAY BRAINSWAY

BrainsWay Announces $5 Million Minority-Stake Investment in Stella MSO...

BrainsWay Announces $5 Million Minority-Stake Investment in Stella MSO, LLC BrainsWay is actively evaluating similar investments in other leading U.S. mental health providers to raise awareness and expand access to transformative care BURLINGTON, Mass. and JERUSALEM, June 04, 2025 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced it has entered into a strategic equity financing agreement with Stella MSO, LLC (“Stella Mental Health” or “S...

June 4, 2025 1 EN
 PRESS RELEASE
Free
BWAY BRAINSWAY

BrainsWay Reports First Quarter 2025 Financial Results and Operational...

BrainsWay Reports First Quarter 2025 Financial Results and Operational Highlights Achieved record quarterly sales of $11.5 million in Q1 2025, an increase of 27% compared to Q1 2024 Operating profit totaled $0.6 million and Adjusted EBITDA rose to $1.3 million, increasing by 519% and 81%, respectively, compared to Q1 of 2024 Shipped a record net number of Deep TMS Systems, indicating significant demand and further strengthening of relationships with enterprise accounts Company is reiterating its full-year 2025 financial guidance, including revenue of $49 to $51 million, ope...

May 13, 2025 1 EN
 PRESS RELEASE
Free
BWAY BRAINSWAY

BrainsWay to Showcase Deep TMS at the 2025 American Psychiatric Associ...

BrainsWay to Showcase Deep TMS at the 2025 American Psychiatric Association Annual Meeting in Los Angeles Exhibit Booth Demonstrations and Participation in Expert Master Course Highlight BrainsWay’s Expanding Role in Psychiatric Care BURLINGTON, Mass. and JERUSALEM, May 01, 2025 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, is proud to announce its participation at the American Psychiatric Association (APA) Annual Meeting, taking place May 17–21, 2025, in Los Angeles, California....

May 1, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch